InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.82
(
-0.37%
)
Bitcoin
64,235.19
(
0.37%
)
Post# of 251721
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 826
Posts 119569
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jb_118 post# 107892

Tuesday, 11/02/2010 5:14:31 PM

Tuesday, November 02, 2010 5:14:31 PM

Post# of 251721
I think an at-risk Copaxone launch is very unlikely without a favorable ruling from the District Court. If NVS/MNTA (and now MYL) prevail against Teva in the District Court, NVS/MNTA might decide to launch before a decision is rendered by the appellate court (assuming that they had FDA approval by then).

The 30-month Hatch-Waxman stay is now irrelevant in the Copaxone case; it will run out before the patent trial has even started.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up